Literature DB >> 31000591

Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses.

Daisuke Sugiura1, Takumi Maruhashi1, Il-Mi Okazaki1, Kenji Shimizu1, Takeo K Maeda1, Tatsuya Takemoto2, Taku Okazaki3.   

Abstract

Targeted blockade of PD-1 with immune checkpoint inhibitors can activate T cells to destroy tumors. PD-1 is believed to function mainly at the effector, but not in the activation, phase of T cell responses, yet how PD-1 function is restricted at the activation stage is currently unknown. Here we demonstrate that CD80 interacts with PD-L1 in cis on antigen-presenting cells (APCs) to disrupt PD-L1/PD-1 binding. Subsequently, PD-L1 cannot engage PD-1 to inhibit T cell activation when APCs express substantial amounts of CD80. In knock-in mice in which cis-PD-L1/CD80 interactions do not occur, tumor immunity and autoimmune responses were greatly attenuated by PD-1. These findings indicate that CD80 on APCs limits the PD-1 coinhibitory signal, while promoting CD28-mediated costimulation, and highlight critical components for induction of optimal immune responses.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2019        PMID: 31000591     DOI: 10.1126/science.aav7062

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  104 in total

1.  Cowpox virus encodes a protein that binds B7.1 and B7.2 and subverts T cell costimulation.

Authors:  Xiaoli Wang; Sytse J Piersma; Jabari I Elliott; John M Errico; Maria D Gainey; Liping Yang; Christopher A Nelson; Wayne M Yokoyama; Daved H Fremont
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-01       Impact factor: 11.205

Review 2.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

3.  Lipid Metabolism and Immune Checkpoints.

Authors:  Qianjin Liao; Yujuan Zhou; Longzheng Xia; Deliang Cao
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells.

Authors:  Natsumi Maeda; Takumi Maruhashi; Daisuke Sugiura; Kenji Shimizu; Il-Mi Okazaki; Taku Okazaki
Journal:  J Biol Chem       Date:  2019-11-13       Impact factor: 5.157

5.  Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.

Authors:  Tania Afroj; Atsushi Mitsuhashi; Hirokazu Ogino; Atsuro Saijo; Kenji Otsuka; Hiroto Yoneda; Makoto Tobiume; Na Thi Nguyen; Hisatsugu Goto; Kazuya Koyama; Masamichi Sugimoto; Osamu Kondoh; Hiroshi Nokihara; Yasuhiko Nishioka
Journal:  J Immunol       Date:  2021-01-27       Impact factor: 5.422

Review 6.  PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.

Authors:  Christopher D Nishimura; Marc C Pulanco; Wei Cui; Liming Lu; Xingxing Zang
Journal:  Trends Mol Med       Date:  2020-11-13       Impact factor: 11.951

7.  The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.

Authors:  Elliot A Philips; Antonio Garcia-España; Anna S Tocheva; Ian M Ahearn; Kieran R Adam; Ruimin Pan; Adam Mor; Xiang-Peng Kong
Journal:  J Biol Chem       Date:  2019-12-27       Impact factor: 5.157

Review 8.  T follicular helper cells in germinal center B cell selection and lymphomagenesis.

Authors:  Michelle A Mintz; Jason G Cyster
Journal:  Immunol Rev       Date:  2020-05-15       Impact factor: 12.988

Review 9.  Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.

Authors:  Kyohei Nakamura; Mark J Smyth
Journal:  Cell Mol Immunol       Date:  2019-10-14       Impact factor: 11.530

10.  Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.

Authors:  Yeni Romero; Randi Wise; Anna Zolkiewska
Journal:  Cancer Immunol Immunother       Date:  2019-12-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.